ACR 70 Response

ACR 70 Response

A measure—based on American College of Rheumatology criteria—of at least a 70% improvement in the number of tender and swollen joints, and a 70% improvement in at least 3 of the following: the patient’s global assessment of disease status; the patient’s assessment of pain; the patient’s assessment of function—measured using the Stanford Health Assessment Questionnaire—the physician’s global assessment of disease status; serum C-reactive protein levels.
References in periodicals archive ?
And more than one-third of the combination group--33% receiving 3 mg/kg and 37% receiving 6 mg/kg--achieved an ACR 70 response versus 21% of the monotherapy group.
In line with the responses of surveyed rheumatologists, interviewed experts consider the ACR 50 and ACR 70 response rates to be more meaningful measures of how a drug will perform in clinical practice than the ACR 20 response rate, despite the fact that the ACR 20 facilitates indirect comparisons among therapies owing to its longstanding use in pivotal trials.
Although the best response rates were in patients on continuous abatacept treatment, even those who at first didn't respond to the drug showed notable responses, with 46% having an ACR 70 response, 18% having an ACR 90 response, and 5% attaining disease inactivity.
At week 24 of treatment, 54 percent of patients achieved an ACR 20 response (a 20 percent collective improvement in rheumatoid arthritis symptoms) 41 percent had an ACR 50 response and 27 percent experienced an ACR 70 response.
Of 28 patients treated with this interleukin 1 receptor antagonist after failing a TNF blocker, only 8% achieved an ACR 20 response, and no patients achieved an ACR 50 or ACR 70 response, she said.
Secondary endpoints at week 24 included ACR 50 and ACR 70 response, Disease Activity Score (DAS) 28 using CRP (DAS28-CRP) response, at least a 75 percent improvement in the Psoriasis Activity Severity Index (PASI 75) in patients with at least 3 percent body surface area involvement at baseline, improvements in enthesitis and dactylitis scores, improvements in HAQ-DI scores and change from baseline in total vdH-S scores.
Rheumatoid Arthristis Response to Abatacept Greater Early in Disease Early disease (duration [less Long-standing disease (duration than or equal to]2 years) > 10 years) ACR 70 Response HAQ Score Improvement of [greater than or equal to]0.
More patients treated with ACTEMRA also achieved major clinical response, defined as achieving an ACR 70 response for a continuous 24-week period, compared to MTX plus placebo.
2 percent of patients in the STELARA 45 mg and STELARA 90 mg groups, respectively, demonstrating ACR 70 response at week 52.
In addition, statistically significantly superior responses were also seen in ACR 50 response rates for the 5, 10 and 15 mg twice daily doses and in the ACR 70 response rates for the 10 and 15 mg twice-daily doses.
ACR 50 and ACR 70 response rates increased from week 24 through week 52 among patients receiving STELARA maintenance therapy.